InsidersTradesSigma
Follow the 현대바이오 share price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 현대바이오 has published 5 reports. Market capitalisation: €659.1bn. The latest transaction was filed on 30 June 2026 (Purchase). Among the most active insiders: 씨앤팜. Every trade is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Hyundai Bio es una empresa que opera en el sector de la salud y farmacéutico, cotiza en el mercado XKRX. Se enfoca en el desarrollo de soluciones biofarmacéuticas innovadoras.